Volume : 10, Issue : 04, April – 2023
Title:
28.A PRACTICE SCHOOL REPORT ON CURRENT TRENDS IN PULMONARY DRUG DELIVERY SYSTEM
Authors :
Samiksha S.Pote, Dr. Monika Jadhao
Abstract :
The pulmonary drug delivery system offers several merits over other drug delivery systems and therefore, this delivery route has been in prime focus for various applications like local and systemic therapeutics delivery. The overall development of drug delivery system depends on its efficacy, quality and safety and to achieve such attributes there is a need of reliable evaluation methods to test them. This review provides an in-depth analysis of the development in the evaluation of pulmonary drug delivery systems. In vitro methods of testing pulmonary products such as particle morphological studies, powder flow characteristics, moisture content test, aerosol turboelectric characterization, particles interparticulate forces measurement and solid state characterizations were discussed. Particle size and zeta potential measurement and evaluation of aerosol performance such as dose uniformity and aerodynamic particle size distribution were reviewed in detail. The development of dissolution methods for pulmonary products is also elaborated. Various cell culture methods for testing pulmonary products were overviewed. The in vivo testing methods including drug administration systems, drug deposition studies and pharmacokinetic studies and ex vivo testing models were also highlighted. Together an overview of current advancement in evaluation and characterization of pulmonary drug delivery system can be analyzed and studied through this review.The pulmonary drug delivery system offers several merits over other drug delivery systems and therefore, this delivery route has been in prime focus for various applications like local and systemic therapeutics delivery. The overall development of drug delivery system depends on its efficacy, quality and safety and to achieve such attributes there is a need of reliable evaluation methods to test them. This review provides an in-depth analysis of the development in the evaluation of pulmonary drug delivery systems. In vitro methods of testing pulmonary products such as particle morphological studies, powder flow characteristics, moisture content test, aerosol turboelectric characterization, particles interparticulate forces measurement and solid state characterizations were discussed. Particle size and zeta potential measurement and evaluation of aerosol performance such as dose uniformity and aerodynamic particle size distribution were reviewed in detail. The development of dissolution methods for pulmonary products is also elaborated. Various cell culture methods for testing pulmonary products were overviewed. The in vivo testing methods including drug administration systems, drug deposition studies and pharmacokinetic studies and ex vivo testing models were also highlighted. Together an overview of current advancement in evaluation and characterization of pulmonary drug delivery system can be analyzed and studied through this review.
Cite This Article:
Please cite this article in press Samiksha S.Pote et al, A Practice School Report On Current Trends In Pulmonary Drug Delivery System., Indo Am. J. P. Sci, 2023; 10 (04).
Number of Downloads : 10
References:
1. Ansel HC, Popovich NG and Allen LV. Pharmaceutical dosage forms and drug delivery systems. Lea & Febiger, Philadelphia; 1990.
2. Chien YW and Banga AK. Iontophoretic (transdermal) delivery of drugs: overview of historical development. Journal of Pharmaceutical Sciences.78 (5); 353-354, 1989
3. Aulton. M. E. Pharmaceutics; The science of dosage form design, second edition, Churchill Livingston, Harcourt publishers-2002.
4. Jain.N.K, Controlled and novel drug delivery, first edition, CBS publishers and distributors, New Delhi. 1997.
5. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastro-retentive dosage forms. J Control Release; 90: 143-62, 2003
6. Thorat and Santosh: Formulation and product development of nebulizer inhaler: An overview. Inc Pharmaceut Sci Res; 5: 30-35, 2016
7. Perkins W: Performance of PARI eFlow® To the Editor. Journal of Aerosol Medicine And Pulmonary Drug Delivery; 23: 113-14, 2010
8. Shubham Prajapati, Sanjay Saha, C. Dilip Kumar: Nebulized Drug delivery:An overview
9. ,International Journal of Pharmaceutical Sciences and Research; 10(8): 3575-3582, 2019
10. Aijaz A.Sheikh, subhash V.Deshmane, Kailash R.Biyani: A Text Book of Novel Drug
11. ChienY.W., Su K.S.E., Chang S.F., Nasal Systemic Drug Delivery, Ch. Marcel-Dekker, New York, 1: 1-77.
12. Illum.L, Jorgensen. H, Bisgard. Hand Rossing. N, Bioadhesivemicrospheres as a potential nasal drug delivery system. Int. J. of Pharmaceutics, 189-199.
13. Akwete, A.L., Gupta, P.K., Eds.; Niven, delivery of biotherapeutics by inhalation aerosol. In Inhalation Delivery of Therapeutic Peptides and Proteins; Marcel Dekker, Inc., NewYork; 151–231, 1997
14. Patton, J.S. Mechanisms of macromolecule absorption by the lungs: Adv. Drug Delivery Rev; 3–36, 1996np,https://en.m.wikipedia.org/wiki/Lung)
15. Aulton ME. Pharmaceutics – The Science of Dosage form Design. New York: Churchill Livingston; 494, 2002
16. Johnson NJ, Hanson LR, Frey WH. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm; 7: 884-93, 2010
17. Svensson S, Olin AC, Hellgren J. Increased net water loss by oral compared to nasal expiration in healthy subjects. Rhinology; 44: 74-7, 2006
18. Rudman KL, O’Brien EK, Leopold DA. Radiographic distribution of drops and sprays within the sinonasal cavities. Am J Rhinol Allergy; 25: 94-7, 2011
19. Hammarlund-Udenaes M, de Lange E, Thorne RG. Pharmacokinetic concepts in brain drug delivery in drug delivery to the brain. In: Physiological Concepts, Methodologies and Approaches. New York: Springer; 127-61, 2014
20. Harmon BT, Aly AE, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL, et al.
21. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Ther; 21: 514-21, 2014
22. Kaye RS, Purewal TS, Alpar OH. Development and testing of particulate formulations for the nasal delivery of antibodies. J Control Release; 135: 127-35, 2009
23. Hardy JG, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol; 37: 294-7, 1985
24. Haque S, Md S, Sahni JK, Ali J, Baboota S. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res; 48: 1-2, 2014
25. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, et al. Receptor occupancy and brain free fraction. Drug Metab Dispos; 37: 753-60, 2009
26. Dinanath G, Padmini K, Dipak M, Namdeo J. Development of particulate mucoadhesive gel for intranasal delivery. Asian J Pharm Clin Res; 10: 222, 2017
27. Kritika S, Bhupen K, Banasmita K. Development and characterizationof mucoadhesive microsphere-loaded intranasal gel of venlafaxine hydrochloride. Asian J Pharm Clin Res ; 9: 139-44, 2016
28. Giuliani A, Balducci AG, Zironi E, Colombo G, Bortolotti F, Lorenzini L, et al. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv; 25: 376-87, 2018
29. Ravikumar R, Balan R, Ganesan N, Thiruvengadam D. Recent modalities in drug delivery via inhalation therapy – An advanced treatment strategy for pulmonary carcinoma. Int J Pharm Pharm Sci; 7: 8-21, 2015
30. Mosab A. Approaches to achieve an oral controlled release drug delivery system using polymers: A recent review. Int J Pharm Pharm Sci; 7: 16-21, 2025
31. Özer AY. The importance of intranasal route for application of drugs and nasal drug delivery systems. Pharm JTPA; 30: 136-47, 1990
32. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clear-ance in rhesus monkeys, Aerosol Sci. Technol; 18: 241–249, 1993
33. Knoch, M. & Finlay, W. H. “Nebulizer Technologies”, Chapter 71 in Modified-Release Drug Delivery Technology, ed. Rathbone/Hadgraft/Roberts, Marcel Dekker;849-856, 2002
34. A J. Hickey, Pharmaceutical Inhalation Aerosol Technology, Marcel Dekker, NY, 2:558
35. Mygind N., Vesterhauge S., Aerosol distribution in the nose, Rhinology; 16: 79–88, 1978
36. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clear-ance in rhesus monkeys, Aerosol Sci. Technol; 18: 241–249, 1993
37. Alagusundaram M., Deepthi N., Ramkanth S., Angala-parameswari S., Mohamed Saleem T.S., Gnanapra-kash K.. Thiruvengadarajan V. S, Madhusudhana Chetty C, Dry Powder Inhalers – An Overview ,Int. J. Res. Pharm. Sci; 1(1): 34-42, 2010
38. Finlay, Warren H. The mechanics of inhaled pharmaceutical aerosols: an introduction. Boston: Academic Press; ISBN 0-12-256971-7, 2001
39. Newhouse M.T., Advantages of pressured canister me-tered dose inhalers, J. Aerosol Med; 4: 139–150, 1991
40. Coro DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci; 79: 202-206, 1990
41. Bawarshi RN, Hussain A, Crooks PA. Nasal absorption of 17a- ethinyloestradiol in the rat. J Pharm Pharmacol; 41: 214-215, 1989
42. Lee V.H.L., Enzymatic barriers to peptide and protein absorption, CRC Crit. Rev. Ther. Drug Carrier Syst; 5: 69–97, 1988
43. Inagaki M, Sakakura Y, Itoh H, Ukai K, Miyoshi Y. Ma-cromolecu- lar permeability of the tight junction of human nasal mucosa. Rhinology; 23: 213-221, 1985
44. Franz, M.R., Oth, M.P., U.S patent; 5232704, 1993
45. Jorissen, M., AND Bessems, A., Eur. Arch. Otorhinolar ngol; 252: 451-454, 1995
46. Arora P, Sharma S, Garg S. Permeability issues in nasal drug deliv- ery. Drug Discov Today; 7(18): 967-975, 2002
47. Satish BB, adhikrao VY, Amelia MA, Rajkumar M, Bio availability of intranasal drug delivery system, Asian J of Pharmaceutics; 201-15, 2008
48. Ohwaki K, Ando H, Watanabe S, Miyake Y, Effects of dose, pH and osmolarity on nasal absorption of se-cretin in rats, J Pharm Sci; 74: 550-2, 1985
49. Gizurarson S, Bechgaard E. Intranasal administration of insulin to humans. Diabetes Res Clin Prac; 12: 71-84, 1991
50. Rohan Bhavane, Efstathios Karathanasis, Ananth V. Annapragada, “Agglomerated vesicle technology”: a new class of particles for controlled and modulated pulmonary drug delivery, Journal of Controlled Release; 15– 28, 2003
51. P.P.H. Le Brun, A.H. de Boer, H.G.M. Heinemann and H.W. frijlink “A review of the technical aspects of drug nebulization”, Pharm World Sci; 22(3): 75‐81, 2000
52. CheinYW, KSE.Su and S.F.Chang. Nasal systemic drug delivery. Dekker; 1‐77, 1989
53. Hicke AJ. Pharmaceutical Inhalation Aerosol Technology. 2nd ed. New York: Marcel Dekker, Inc.; 2004.
54. Sharma PK, Chaudhari P, Kolsure P, Ajab A, Varia N. Recenttrends in nasal drug delivery system – An overview. ARPB; 5:4, 2006
55. Ramadan HH, Sanclement JA, Thomas JG. Chronic rhinosinusitis and biofilms. Otolaryngol Head Neck Surg 132:414-7, 2005
56. Mahita B, Vinod K. A clinic opathological study of allergic rhinitis. Asian J Pharm Clin Res;10:186-91, 2017
57. Shanu T, Nitin S, Sharma PK. A review on application of natural bio adhesive polysaccharides for intranasal drug delivery. Int J A.PS.BMS; 1:80-94, 2012
58. Zaheer A, Swamy S. Mucoadhesive polymers: Drug carriers for improved nasal drug delivery. Indian J Novel Drug Deliv; 4:2-16, 2012
59. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery Novel Carrier System. 1st ed. New Delhi: CBS Publishers and Distributors; p. 173, 2006
60. Mahalaxmi R, Kumar DS, Shirwaikar A. preparation of mucoadhesive microsphere for nasal delivery by spray drying. Indian J Pharm Sci; 69:651-7, 2007
61. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci; 12:288-311, 2009